Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
about
Stable alteration of pre-mRNA splicing patterns by modified U7 small nuclear RNAsSystematic review: Hydroxyurea for the treatment of adults with sickle cell diseaseBiomarkers and recent advances in the management and therapy of sickle cell diseaseOral citrulline as arginine precursor may be beneficial in sickle cell disease: early phase two resultsRisk Factors of Pulmonary Hypertension in Brazilian Patients with Sickle Cell AnemiaPrimary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigmHydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectinManagement of sickle cell disease: recent advances and controversies.Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA).Apolipoprotein A-I and serum amyloid A plasma levels are biomarkers of acute painful episodes in patients with sickle cell diseaseAntisickling property of fetal hemoglobin enhances nitric oxide bioavailability and ameliorates organ oxidative stress in transgenic-knockout sickle mice.Treating sickle cell disease by targeting HbS polymerizationThe risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up.Management of cerebral vasculopathy in children with sickle cell anaemia.Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model.Acute chest syndrome: sickle cell disease.Immunologic effects of hydroxyurea in sickle cell anemia.Imaging flow cytometry for automated detection of hypoxia-induced erythrocyte shape change in sickle cell disease.Hydroxyurea for sickle cell disease.Developing treatment for sickle cell disease.Sickle red cell-endothelium interactions.Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease.Newer aspects of the pathophysiology of sickle cell disease vaso-occlusion.Hydroxyurea and sickle cell anemia: effect on quality of life.Safety of short-term valacyclovir as an anti-sickling agent in sickle-cell anemia.Hydroxyurea therapy mobilises arachidonic Acid from inner cell membrane aminophospholipids in patients with homozygous sickle cell diseaseQuantification of sickle cells in the peripheral smear as a marker of disease severity.The proinflammatory cytokine GM-CSF downregulates fetal hemoglobin expression by attenuating the cAMP-dependent pathway in sickle cell disease.Sickle cell disease: old discoveries, new concepts, and future promise.Pharmacological induction of fetal hemoglobin synthesis using histone deacetylase inhibitors.Phase 1 Study of a Sulforaphane-Containing Broccoli Sprout Homogenate for Sickle Cell DiseaseIon transport pathology in the mechanism of sickle cell dehydration.Integrating interactive web-based technology to assess adherence and clinical outcomes in pediatric sickle cell disease.Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children.HMGA2 Moderately Increases Fetal Hemoglobin Expression in Human Adult Erythroblasts.Antisickling fetal hemoglobin reduces hypoxia-inducible factor-1α expression in normoxic sickle mice: microvascular implications.Synthetic methodology for the preparation of N-hydroxysulfamides.Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology.Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease.Fetal hemoglobin and hydroxycarbamide moduate both plasma concentration and cellular origin of circulating microparticles in sickle cell anemia children.
P2860
Q24569504-F2BC832B-0F91-4059-82B1-9AC603DE5717Q24610970-18EC242B-6797-49BB-8D08-5A9A7D24D44AQ28082462-CD2E724B-7AFF-4E85-8286-1A139133D6B7Q28363043-6331F922-2950-4B44-8B4D-003C0BDE305DQ28547742-7980255A-9849-469F-96B2-A75F1205FEB6Q30476171-722028A7-95A9-42FA-8133-52D41CB6581FQ30506249-CD68B8DA-45EF-4A57-AC21-01C629833AC8Q30790662-89A3942E-B153-43B4-808F-19DAD20E35BFQ33345042-EBA3A5F3-657F-4EEC-AC7A-4792C0A14336Q33551127-3382E4F8-A43C-4C01-B691-3F194AF9A09AQ33686611-014BDCA0-FDE5-4C84-87C4-BFA2818CB50EQ33707352-B66B25B0-9D9B-44C5-8584-B12409DBEEA8Q33890227-2C352565-E35A-407E-8B1A-539818CE9E37Q33904379-67DCC608-E25C-4105-98E5-8A6771FF92A0Q34095672-5F7BF9B5-FF10-44D3-8181-4D1045523D39Q34187526-D8EAF1DF-1DD9-4652-A65B-1D1C5740046AQ34263125-4D2BD77C-C345-42C8-ADA9-C505556C28C8Q34266987-72D4640D-2321-4FCD-8A29-DA5856D533D4Q34281892-8EC5E662-992F-472B-BDC2-94E118E8C7CEQ34628666-F26DDFDE-6441-41B4-B5C8-07BBE095491BQ34686539-785D1BB0-14E7-4630-916E-A84B9EC980A4Q34723434-04397AD0-EF7F-4641-A66B-80DAC9F3F21FQ34941213-3F25249A-172B-4436-9EE7-B3233BDA39D3Q35038868-5F103DF7-4DF5-42F4-BD97-646BFD4C1B10Q35112797-10734FDC-83DF-4838-A9CE-AB3EFA6FC4A3Q35215166-269C2637-9143-4FBE-A29F-0CCF1D8583B5Q35527101-9080AC31-4F3F-4C8E-B24C-A46240DE1C90Q35571071-17A42DCF-E129-4FA2-8710-02FF7603D5DFQ35723452-3C9BB787-BE25-48F7-9D42-B4CA61BB8474Q35809469-F7FD3A58-30B0-4D1F-B44A-15846CA4BDB1Q35987429-A5773352-44FF-4E04-A667-BE91CB5024C2Q35993299-52C9F9A6-E6E2-4425-A590-585BE107EEC2Q36023769-2EDCCFB1-6881-4AD4-ADC1-5AD761BBC6CAQ36028317-AFC3FEFF-2C1E-4F49-BBD0-598488931E59Q36197405-D3F33F56-A533-47C7-8121-CF1CE168747FQ36528107-5F0BD224-1642-4F93-813C-E66BAD06EA97Q36580861-0A53C96F-EE1C-44C0-B69E-29AF6EB525D9Q36596850-61894238-099D-4457-A064-C0576A339D24Q36596855-6BAD27E5-29B7-4892-8B4F-3A91ECD84450Q36892578-166AB4DB-CC5C-4FCF-A182-26D166264532
P2860
Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Hydroxyurea and sickle cell an ...... oxyurea in Sickle Cell Anemia.
@en
type
label
Hydroxyurea and sickle cell an ...... oxyurea in Sickle Cell Anemia.
@en
prefLabel
Hydroxyurea and sickle cell an ...... oxyurea in Sickle Cell Anemia.
@en
P2093
P1433
P1476
Hydroxyurea and sickle cell an ...... oxyurea in Sickle Cell Anemia.
@en
P2093
Charache S
McMahon RP
Orringer EP
P304
P356
10.1097/00005792-199611000-00002
P407
P577
1996-11-01T00:00:00Z